drugset / Trial / NCT02322229
Ocriplasmin for Vitreomacular Traction/Symptomatic Vitreomacular Adhesion
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to observe the anatomical and functional outcomes of ocriplasmin (JETREA™®) over a 6-month period.
Timeline
- Start
- 2015-05-26
- Primary completion
- 2015-12-11
- Completion
- 2016-05-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ocriplasmin | Protein / enzyme biologic | 0.125 mg | Intravitreal |